Season 4 - Episode 2

In the second episode of ILCA’s Liver Cancer Podcast, hosted by Sarah Cappuyns, MD, PhD, a Gastroenterology resident and member of the Y-ILCA Committee, we are joined by Jeroen Dekervel, Digestive Oncologist at the University Hospital in Leuven, Belgium.

In this episode, they engage in a discussion on the emerging role of biomarkers in guiding systemic therapy for hepatocellular carcinoma (HCC). They explore the need for reliable biomarkers to predict treatment response and tailor therapeutic approaches in HCC. The conversation highlights the most promising biomarkers currently being investigated, including those related to immunotherapy and targeted treatments and discusses their potential impact on the future of precision medicine in HCC management.

Season 4 - Episode 1

In this new episode of ILCA’s Liver Cancer Podcast, we kick off our 2025 series with an insightful discussion on the latest advancements in hepatocellular carcinoma (HCC) surveillance.

Hosted by Coskun Ozer Demirtas, Associate Professor of Gastroenterology & Hepatology at Marmara University (Turkey) and member of ILCA’s Young Investigators Committee, this episode features Amit Singal, transplant hepatologist and medical director of the liver cancer program at UT Southwestern in Dallas, TX.

Together, they explore the latest updates and future directions for HCC surveillance, focusing on ILCA’s white paper on HCC risk stratification and surveillance. Developed from the ILCA Single Topic Workshop held in June 2022, the white paper outlines the current state of the field, ongoing research, and challenges in translating new strategies into clinical practice.

Season 3 - Episode 9

In this episode, sponsored by Roche, we delve into the groundbreaking findings from the IMbrave150 trial, focusing on the efficacy and safety of Atezolizumab plus Bevacizumab versus Sorafenib in patients with hepatocellular carcinoma (HCC) exhibiting main trunk and/or contralateral portal vein invasion. Join experts Amit Singal and Richard Finn as they break down the key results of this pivotal study, discussing the clinical implications for treatment strategies in advanced liver cancer.

Season 3 - Epiosode 8

In this episode, sponsored by Roche, David Pinato and Manon Allaire delve into the use of real-world research data and its implications. They share insights from their professional experiences with collecting, cleaning, and organizing this data. Clinical trial results often differ from real-world data, and our guests explore the gap between the two and its potential consequences. Finally, they discuss how real-world evidence is shaping the future of our profession.

Season 3 - Episode 7

In this episode, Joana Espírito Santo and Julien Calderaro explore the diagnostic complexity and the treatment and prognosis pitfalls of combined hepatocellular-cholangiocarcinomas (cHCC-CCAs). They reflect on the heterogeneity of these tumours and the potential impact of AI-based phenotyping, highlighting the importance of combining biopsy and imaging as an integrative approach.

Listen to this episode of the ILCA podcast for a captivating discussion addressing the perspectives and challenges of cHCC-CCAs.

Season 3 - Episode 6

In this episode, Lorenza Rimassa, Andrew Moon, and Jakob Kather discuss ways to enhance tumor board effectiveness. Lorenza emphasizes the importance of multidisciplinary collaboration, Andrew highlights patient representation, and Jakob explores the integration of AI. Listen to them as they engage in insightful exchanges, addressing questions and offering innovative solutions.

This episode is sponsored by Roche, a global pioneer in pharmaceuticals and diagnostics. Roche's goal is to partner with the HCC community to provide optimal care and treatment to patients with HCC by supporting the implementation of an MDT approach.

Season 3 -Episode 5

Meet Antonio D'Alessio and Claudia Campani, two of the best oral presenters from the ILCA 2023 Annual Conference. Antonio will present and discuss his work "Predictors of response to neoadjuvant immunotherapy in resectable hepatocellular carcinoma: preliminary clinical and translational analyses from the PRIME-HCC study". Claudia will present her work "Dynamic evolution of circulating tumor DNA in patients with hepatocellular carcinoma across tumor stages and treatments".

Incyte has co-funded this podcast and all content has been developed independently by ILCA.

Season 3 - Episode 4

In this episode, Dr Taizo Hibi and Dr Cristina Dopazo discuss a recent review article in Hepatoma Research titled: “Liver Transplantation for perihiliar cholangiocarcinoma: Do we need to move forward?". They discuss the outstanding results of the Mayo Clinic protocol based on liver transplantation after neoadjuvant chemoradiation in very selected patients with unresectable de novo pCCA or resectable pCCA arising under primary sclerosing cholangitis. However, its application is diverse worldwide. They also discuss the recommended tools for diagnostic work-up, the need for updating the systemic therapy following the results of the latest clinical trials, the role of cfDNA, and the importance of multicenter collaborations.

This episode is sponsored by Hepatoma Research.

Season 3 - Episode 3

This episode discusses a recent review article in Hepatoma Research titled: "Challenges and Barriers in Hepatocellular Carcinoma Surveillance for Patients with non-alcoholic Fatty Liver Disease" (now called metabolic associated steatotic liver disease or MASLD). We discuss several important challenges and barriers that currently exist in caring for patients with MASLD cirrhosis, including the scale of the MASLD – hepatocellular carcinoma problem, the current lack and limitations of accurate risk stratification tools in order to improve detection and prevention of HCC in patients with MASLD cirrhosis, potential solutions to address these limitations, and ends with a discussion of current disparities that exist in HCC surveillance.

This episode is sponsored by Hepatoma Research.

In this episode, Drs. Maria Reig and Richard Finn will dive deep into the updates and groundbreaking research presented at the ASCO GI Meeting in January 2023. They will explore the latest advancements in the field of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Here is what you can expect from this podcast:

• Updates on the efficacy and safety of new drugs in HCC

• The evolving landscape of systemic therapy for cholangiocarcinoma

• Evolving questions in sequencing systemic therapy in HCC

• The role of systemic therapy in the early stages of HCC

Incyte has co-funded this podcast and all content has been developed independently by ILCA.